BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36599413)

  • 1. Unprecedented long-term survival in a patient with malignant pleural mesothelioma treated with subsequent systemic chemo- and immunotherapeutic regimens.
    Cerbone L; Delfanti S; De Angelis AM; Crivellari S; Boccuzzi F; Cimorelli A; Bertolotti M; Righi L; Bertino P; Grosso F
    Thorac Cancer; 2023 Feb; 14(5):524-527. PubMed ID: 36599413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
    Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
    Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What's Current and What's New in Mesothelioma?
    Leal JL; Hoang W; Xue J; Dunne B; John T; Harden S
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):771-780. PubMed ID: 36155156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
    Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
    Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
    Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma.
    Karatkevich D; Deng H; Gao Y; Flint E; Peng RW; Schmid RA; Dorn P; Marti TM
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
    Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
    Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Fujimoto N; Aoe K; Kozuki T; Oze I; Kato K; Kishimoto T; Hotta K
    Clin Lung Cancer; 2018 Sep; 19(5):e705-e707. PubMed ID: 29853412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Advanced Pleural Mesothelioma-At the Crossroads.
    Nowak AK; Jackson A; Sidhu C
    JCO Oncol Pract; 2022 Feb; 18(2):116-124. PubMed ID: 34491782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced epithelioid pleural mesothelioma, long lasting disease stabilization and long term survival with cisplatin-pemetrexed chemotherapy re-challenge: a case report.
    Cirino C; Veltri E
    Clin Ter; 2016; 167(1):10-2. PubMed ID: 26980632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
    Cui W; Popat S
    Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma.
    Zhang D; Liang J; Lv Y; Huang X; Guo W
    Medicine (Baltimore); 2022 Dec; 101(52):e32459. PubMed ID: 36596035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapies for malignant pleural mesothelioma.
    Scherpereel A; Wallyn F; Albelda SM; Munck C
    Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
    Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
    Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
    Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant pleural mesothelioma: an update on diagnosis and treatment options.
    Kondola S; Manners D; Nowak AK
    Ther Adv Respir Dis; 2016 Jun; 10(3):275-88. PubMed ID: 26873306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.